A multiple ascending dose study of GR3027 for the treatment of Hepatic Encephalopathy

Trial Profile

A multiple ascending dose study of GR3027 for the treatment of Hepatic Encephalopathy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs GR 3027 (Primary)
  • Indications Hepatic encephalopathy
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2017 According to a Karolinska Development media release, phase 1b portion of this trial is completed.
    • 13 Sep 2017 According to a Karolinska Development media release, results of phase 2a portion expected during 2018 .
    • 13 Sep 2017 Results from Phase Ib portion (n=18) published in the Karolinska Development Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top